新辅助化疗对乳腺癌p170、Ki67、p53的影响

Altered expression of p170, Ki67 and p53 in primary breast carcinoma after neoadjuvant chemotherapy

目的了解乳腺癌对新辅助化疗的反应性以及与相关生物学标志物的关系并探讨其机制。方法37例新诊断为T2-3N0-1M0期的乳腺癌患者术前给予CTF(cyclophosphamide,环磷酰胺;pirarubicin,吡喃阿霉素;5-fluorouracil,氟尿嘧啶)方案化疗2个周期,在化疗前、后分别观察癌组织中p170、Ki67、p53的表达情况及与化疗疗效的关系。结果本组患者经2个周期化疗后,部分缓解和轻度缓解分别为27.0%和54.1%;化疗前p170的表达率为18.9%,经化疗后表达率升高至43.2%(P<0.05);Ki67在化疗前、后表达率分别为32.4%和10.8%(P<0.05);p53无明显变化。结论CTF方案新辅助化疗有一定疗效,经化疗后反映残留癌细胞多药耐药的p170表达呈增加趋势,而反映细胞增殖的Ki67表达呈下降趋势。

Objective： To test the expression of p170, Ki67, and p53 in breast cancer after neoadjuvant chemotherapy. Methods：Thirty-seven patients were diagnosed as T2-3N0-1M0, breast cancer. They received 3-week CTF regimen （cyclophosphamide, pirarubicin hydrochloride,and 5-fluorouracil） for 2 cycles before surgery. Expressions of p170, Ki67, and p53 were measured by immunohistochemistry. Results： After 2-cycte neoadjuvant chemotherapy, 27. 0% patients had partial responses and 54.0% patients had minor responses. There was an increase in p170 expression （45.7% vs 18.9% ,P〈0.05） and a decrease in Ki67 expression （ 11.4 % vs 32. 4%, P〈0. 05 ）. The expression of p53 had no significant changes. Conclusion： Neoadjuvant chemotherapy with CTF regimen is effective, After neoadjuvant chemotherapy p170 was increased but Ki67 was decreased.